6-Apr-2026
No headlines found.
Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer
Business Wire (Mon, 16-Mar 4:05 PM ET)
Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results
Business Wire (Mon, 2-Mar 4:01 PM ET)
Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference
Business Wire (Fri, 20-Feb 8:30 AM ET)
Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026
Business Wire (Tue, 17-Feb 4:01 PM ET)
Business Wire (Thu, 22-Jan 7:30 AM ET)
Business Wire (Sun, 11-Jan 4:00 PM ET)
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
Cerus trades on the NASDAQ stock market under the symbol CERS.
As of April 6, 2026, CERS stock price declined to $1.85 with 1,007,103 million shares trading.
CERS has a beta of 1.34, meaning it tends to be more sensitive to market movements. CERS has a correlation of 0.15 to the broad based SPY ETF.
CERS has a market cap of $353.65 million. This is considered a Small Cap stock.
Last quarter Cerus reported $58 million in Revenue and -$.01 earnings per share. This fell short of revenue expectation by $-2 million and met earnings estimates .
In the last 3 years, CERS traded as high as $3.08 and as low as $1.12.
The top ETF exchange traded funds that CERS belongs to (by Net Assets): ARKK, VTI, ARKG, IWM, VXF.
CERS has outperformed the market in the last year with a price return of +32.1% while the SPY ETF gained +18.0%. However, in the short term, CERS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -6.1% vs -3.3% return in SPY. But in the last 2 weeks, CERS shares have fared better than the market returning +5.1% compared to SPY +0.4%.
CERS support price is $1.78 and resistance is $1.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CERS shares will trade within this expected range on the day.
